Abstract
Protease inhibitor-encapsulated human insulin microspheres were developed and evaluated in this research in order to determine the optimal formulation. Manufacturing human insulin microspheres involved coating them with eudragit S-100, stabilizing them with polyvinyl alcohol, and evaporating the solvent from w/o/w multiple emulsions. Excellent encapsulation efficiency and pH-dependent controlled release were demonstrated by human insulin-loaded eudragit L-100 microspheres with a protease inhibitor. This helped encapsulate and transfer insulin to the best absorption zone. Thus, insulin absorption and physiological response increased. Thus, insulin formulations enhance efficacy, making microsphere insulin injection more efficient as a diabetic treatment. Drug-polymer ratio affects microsphere size and form. The effect of emulsifying agent amount on microsphere size and manufacturing yield. Eudrajit RL, microspheres loaded with insulin, are more successfully formulated and manufactured at optimal concentrations of polymer and emulsifying agent
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
